Immix Biopharma, Inc.
IMMX
$8.18
$0.172.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 67.82% | 12.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.16% | 14.06% | |||
| Operating Income | -42.16% | -14.06% | |||
| Income Before Tax | -40.89% | -14.58% | |||
| Income Tax Expenses | 46.75% | -13.48% | |||
| Earnings from Continuing Operations | -40.89% | -14.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -40.89% | -14.54% | |||
| EBIT | -42.16% | -14.06% | |||
| EBITDA | -43.30% | -13.61% | |||
| EPS Basic | -11.83% | -7.56% | |||
| Normalized Basic EPS | -11.87% | -7.54% | |||
| EPS Diluted | -11.83% | -7.56% | |||
| Normalized Diluted EPS | -11.87% | -7.54% | |||
| Average Basic Shares Outstanding | 25.99% | 6.48% | |||
| Average Diluted Shares Outstanding | 25.99% | 6.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||